Aditxt, Inc. Accrued Marketing Costs, Current
Aditxt, Inc. (ADTX) had Accrued Marketing Costs, Current of $402.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedMarketingCostsCurrent · last filed 2026-03-31
- 2025-12-31: Accrued Marketing Costs, Current $402.00K.
- 2025-09-30: Accrued Marketing Costs, Current $405.99K.
- 2025-06-30: Accrued Marketing Costs, Current $399.95K.
- 2025-03-31: Accrued Marketing Costs, Current $50.92K.
| Period end | Accrued Marketing Costs, Current |
|---|---|
| 2025-12-31 | $402.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $405.99K 10-Q · filed 2025-11-18 |
| 2025-06-30 | $399.95K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $50.92K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $197.86K 10-K · filed 2026-03-31 |
| 2024-09-30 | $94.73K 10-Q · filed 2025-11-18 |
| 2024-06-30 | $64.73K 10-Q · filed 2025-08-14 |
| 2024-03-31 | $40.51K 10-Q · filed 2025-05-15 |
| 2023-12-31 | $269.28K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |